NZ527720A

NZ527720A - Synthetic vaccine agents

Info

Publication number: NZ527720A
Application number: NZ527720A
Authority: NZ
Inventors: Klaus Gregorius Nielsen; Peter Koefoed
Original assignee: Pharmexa As
Priority date: 2001-02-19
Filing date: 2002-02-19
Publication date: 2005-03-24
Also published as: IL157475A0; CN1893970A; WO2002066056A2; WO2002066056A3; CN100562338C; NO20040431L; ZA200400895B; NO335602B1; EP1363664A2; AU2002233166B2; WO2002066056A8; CA2440197A1; JP2004529881A

Abstract

An immunogen comprises at least one antigenic determinant constituted by an amino acid sequence that includes at least one B-cell epitope and/or at least one CTL epitope, and at least one second antigenic determinant constituted by an amino acid sequence that includes a T helper cell epitope (TH epitope). Each of the antigenic determinants are independently coupled through the nitrogen atoms at their respective NB-termini to a pharmaceutically acceptable activated polyhydroxypolymer carrier via a bond that is cleavable. The immunogen can be used in the manufacture of a medicament for immunizing an animal.

Description

P1015PC00 527720 1 SYNTHETIC VACCINES COMPRISING POLYHYDROXYPOLYMER CARRIERS The present invention provides for novel vaccine agents, which have a controllable distribution of different, well-defined peptides and which allows for detachment of these peptides 5 from the agent by means of peptidase cleavage.

BACKGROUND OF THE INVENTION Agents for immunizing or vaccinating animals include a large variety of different solutions to various problems involved in immunization.

When immunizing with small antigens or haptens, one problem is often the absence of peptide sequences in the immunogen that can trigger CD4+ cells to provide the necessary help for B-cell or CTLs to mount a sufficient immune response. This problem is especially important when the antigen is of self-ori-15 gin.

The traditional approach has been to covalently couple (conjugate) the antigen of interest to a large immunogenic carrier protein. In recent years this technology has been refined by utilising immunogens comprised of short peptide antigens fused 20 to relevant carrier proteins or. even to known universal T-helper epitopes.

However, both of these prior art technologies suffer a number of drawbacks. If using the traditional carrier approach, it is difficult to characterise the resulting product and it is fur-25 ther a problem that the immune response induced will have a tendency to be directed towards the carrier moiety and not to I LLLti i UAL PROPERTY OFFICE OF N.Z. 1 3 JAN 20 P O F' \/ p Pi 2 towards the peptide antigen - this phenomenon is known as "carrier suppression".

Furthermore, when coupling a small peptide to a large carrier, it is normally not predictable whether or not the antigenic 5 determinant(s) of the peptide will be accessible to the immune system, since the carrier moiety to some degree will shield the peptide.

Similar problems exist with fusion of carriers to peptides -this problem is to some extent avoided when using "carriers" 10 that are constituted of short T-helper epitopes. Nevertheless, this may also give rise to problems. Due to the small size of both the peptide and the T-helper epitope, it is not in any way a certain thing that the ratio between T-helper epitopes and antigenic determinant is optimal in order to trigger the 15 most effective immune response.

In conclusion, there is a definite need to device novel strategies for preparing vaccine based on small antigenic peptides or small haptens.

OBJECT OF THE INVENTION It is an object of the present invention to provide for novel immunogenic agents that utilise an inert carrier as a multivalent coupling agent to which one can couple both an antigen of interest but also a controlled amount of T-helper epitopes and/or other immunologically suitable moieties. -It is a fur-25 ther object of the invention to provide for compositions including such immunogenic agents as well as to provide for novel methods of immunization.

WO 02/066056 PCT/DK02/00112 SUMMARY OF THE INVENTION One known way of achieving coupling of peptides to an immunologically inert carrier is to activate a suitable polyhydroxy-polymer with tresyl (trifluoroethylsulphonyl) groups or other 5 suitable activation groups such as maleimido, p-Nitrophenyl cloroformate (for activation of OH groups and formation of a peptide bond between peptide and polyhydroxypolymer), and to-syl (p-toluenesulfonyl). It is e.g. possible to prepare activated polysaccharides as described in WO 00/05316 and US 10 5,874,469 (both incorporated by reference herein) and couple these to peptides that have been prepared by means of conventional solid or liquid phase peptide synthesis techniques. The resulting product consists of a polyhydroxypolymer backbone (e.g. a dextran backbone) that has, attached thereto by their 15 N-termini or by other available nitrogen moieties, peptides of choice.

This known way of coupling peptides (or other suitable antigenic determinants) to e.g. tresylated water-soluble dextran has to the best of the present inventors' knowledge previously 20 merely been contemplated for dianogstic uses. However, the present inventors have now surprisingly discovered that such peptide-polyhydroxypolymer conjugates are very suitable as agents for immunisation. This has been demonstrated in a series of experiments where a mixture of a C-terminal peptide 25 (the 8 C-terminal amino acids) from the Borrelia antigen OspC and a known TH epitope peptide was coupled to a tresyl-acti-vated dextran and used as an immunization .agent in mice.

However, this principle or coupling a peptide antigen to a polyhydroxypolymer is in the opinion of the present inventors 30 a generally applicable, novel and inventive approach: 4 Molecules can be obtained that comprise a T helper epitope and molecules representing or including B-cell epitopes linked co-valently to a non-immunogenic polymer molecule acting as a vehicle, e.g. a multivalent activated poly-hydroxypolymer - this 5 type of molecule functions as a vaccine molecule that only contains the immunologically relevant parts of antigens. Promiscuous or so-called universal T-helper epitopes can be used if e.g. the target for the vaccine is a hapten (such as a self-antigen) or an antigen that otherwise could be rendered 10 more immunogenic by adding further TH epitopes. Furthermore, elements that enhance the immunological response could be also co-coupled to the vehicle and thereby act as an adjuvant. Such elements could be mannose, tuftsin, muramyl dipeptide, CpG motifs etc, cf. below. In that case, subsequent adjuvant formu-15 lation of the vaccine product might be unnecessary and the product could be administered in pure water or saline.

By coupling cytotoxic T cell (CTL) epitopes together with the T-helper epitopes it will also be possible to generate CTL's specific for the antigen from which the CTL epitope was de-20 rived. Elements that promote uptake of the product to the cy-tosol, such as mannose, of the APC, e.g. a macrophage, could also be co-coupled to the vehicle together with the CTL- and the T helper epitope and enhance the CTL response.

Hence, in its most broad and general scope, the present inven-25 tion provides for a novel immunogen which comprises a) at least one first antigenic determinant that includes at least one B-cell epitope and/or at least one CTL epitope, and b) at least one second antigenic determinant that in-30 eludes a T helper cell epitope (TH epitope), wherein each of the at least one first and second antigenic determinants are coupled to a pharmaceutically acceptable activated polyhydroxypolymer carrier.

Another aspect of the invention relates to an immunogenic com-5 position comprising the immunogen of the invention.

A third aspect of the invention relates to a method of immunizing/vaccinating an animal against an antigen of choice by administering the immunogen or the immunogenic composition of the invention, where the immunogen and the antigen of choice 10 shares the same at least one first antigenic determinant.

A fourth aspect of the invention relates to a method for preparing and selecting useful immunogens of the invention.

It should be noted that the present disclosure focuses on the use of antigenic peptide determinants - in fact it is neces-15 sary that the 2nd antigenic determinant is, or at least contains, an amino acid sequence that constitutes an MHC Class II binding peptide (a TH epitope). However, if the 1st determinant includes B-cell epitopes, it need not necessarily be a peptide - it will be understood by the skilled reader that all disclo-20 sures relating to the 1st antigenic determinant may relate to other B-cell epitope-containing molecular entities, unless the present disclosure specifically discusses characteristics of 1st peptide determinants that would not be applicable to other antigenic determinants (for instance in the event the 1st de-25 terminant is a CTL epitope). 6 LEGEND TO THE FIGURE Fig. 1: Schematic drawing of the synthesis of immunogens of the invention, exemplified by peptide-coupling to TAD. A mixture of peptides A and B is brought in contact (essen-5 tially as described in Example 2) with a tresyl-activated, water-soluble dextran. Peptides A and B react with the activation groups on the TAD, and after purification the immunogen is provided.

DETAILED DISCLOSURE OF THE INVENTION 10 Definitions In the following, a number of terms used in the present specification and claims will be defined and explained in detail in order to clarify the metes and bounds of the invention.

The terms "T-lymphocyte" and "T-cell" will be used inter-15 changeably for lymphocytes of thymic origin that are responsible for various cell mediated immune responses as well as for helper activity in antigen specific immune responses. Likewise, the terms "B-lymphocyte" and "B-cell" will be used interchangeably for antibody-producing lymphocytes. The terms 20 "cytotoxic T-cell", "cytotoxic T lymphocyte" and the term "CTL" are also used interchangeably for lymphocytes that induce cell killing in response to recognition of peptide sequences bound to MHC Class I molecules on the surface of the cells.

"An immunogen" is herein meant to designate a single molecule that includes one or more antigenic determinants of an antigen 7 of interest and one or more TH epitopes that are recognized by the animal to be immunized.

"Antigenic determinant" is herein designating a molecule or a part of a molecule that is specifically recognised by certain 5 clones of lymphocytes. An antigenic determinant may e.g. be a B-cell epitope and thus recognized by B-cells and their corresponding antibodies. A B-cell epitope is characterized by its 3D shape and in essence any part of a molecule that can fit into the antigen binding site of an antibody may constitute an 10 antigenic determinant of that molecule. Other antigenic determinants are CTL and TH epitopes - these are always peptides or contains peptides and they are characterized by their linear structure.

The term "peptide" is in the present context intended to mean 15 both short peptides of from 2 to 10 amino acid residues, oligopeptides of from 11 to 100 amino acid residues, and polypeptides of more than 100 amino acid residues. Furthermore, the term is also intended to include proteins, i.e. functional biomolecules comprising at least one polypeptide. The peptide 20 may be glycosylated and/or lipidated and/or comprise prosthetic groups.

The term "subsequence" means any consecutive stretch of at least 3 amino acids or, when relevant, of at least 3 nucleotides, derived directly from a naturally occurring amino acid 25 sequence or nucleic acid sequence, respectively.

The term "animal" is in the present context in general intended to denote an animal species (preferably mammalian), such as Homo sapiens, Canis domesticus, etc. and not just one single animal. However, the term also denotes a population of 30 such an animal species, since it is important that the indi 8 viduals immunized according to the invention all harbour substantially the same antigen allowing for immunization of the animals with the same immunogen(s). If, for instance, genetic variants of the antigen exists in different human populations 5 it may be necessary to use different immunogens in these different populations in order to be able to break the tolerance towards the antigen in each population. It will be clear to the skilled person that an animal in the present context is a living being which has an immune system. It is preferred that 10 the animal is a vertebrate, such as a mammal.

The expression "effecting presentation ... to the immune system" is intended to denote that the animal's immune system is subjected to an immunogenic challenge in a controlled manner. As will appear from the disclosure below, such challenge of 15 the immune system can be by vaccination with peptide-contain-ing immunogens of the invention. The important result to achieve is that immune competent cells in the animal are confronted with the antigen in an immunologically effective manner, whereas the precise mode of achieving this result is of 20 less importance to the inventive idea underlying the present invention.

The term "immunogenically effective amount" has its usual meaning in the art, i.e. an amount of an immunogen which is capable of inducing an immune response which significantly en-25 gages agents (e.g. pathogenic agents) which share immunological features with the immunogen.

When discussing "autotolerance towards an autologous antigen" it is understood that since the relevant antigen is a self-molecule in the population to be vaccinated, normal individu-30 als in the population do not mount an immune response against 9 it; it cannot be excluded, though, that occasional individuals in an animal population might be able to produce antibodies against the native antigen, e.g. as part of an autoimmune disorder. At any rate, an animal species will normally only be 5 autotolerant towards its own antigen, but it cannot be excluded that analogues derived from other animal species or from a population having a different phenotype would also be tolerated by said animal. Furthermore, antigens that lack size or (normally more relevant) TH epitopes are also tolerated by 10 the immune system and these will behave in much the same way as a true self-antigen.

A "foreign T-cell epitope" (or: "foreign T-lymphocyte epitope") is a peptide which is able to bind to an MHC molecule and which stimulates T-cells in an animal species. Preferred 15 foreign T-cell epitopes in the invention are "promiscuous" (or "universal" or "broad-range") epitopes, i.e. epitopes which bind to a substantial fraction of a particular class of MHC molecules in an animal species or population. Only a very limited number of such promiscuous T-cell epitopes are known, 20 and they will be discussed in detail below. It should be noted that in order for the immunogens which are used according to the present invention to be effective in as large a fraction of an animal population as possible, it may be necessary to 1) insert several foreign T-cell epitopes in the same immunogen 25 or 2) prepare several immunogens wherein each analogue has a different promiscuous epitope inserted. It should be noted also that the concept of foreign T-cell epitopes also encompasses use of cryptic T-cell epitopes, i.e. epitopes which are derived from a non-immunogenic protein and which only exerts 30 immunogenic behaviour when existing in isolated form without being part of the non-protein in question.

A "foreign T helper lymphocyte epitope" (a foreign TH epitope) is a foreign T cell epitope which binds an MHC Class II molecule and can be presented on the surface of an antigen presenting cell (APC) bound to the MHC Class II molecule.

An "MHC Class II binding amino acid sequence that is heterologous to an antigen" is therefore an MHC Class II binding peptide that does not exist in the multimeric protein in question. Such a peptide will, if it is also truly foreign to the animal species harbouring the multimeric protein, be a foreign 10 Th epitope.

A "functional part" of a (bio)molecule is in the present context intended to mean the part of the molecule which is responsible for at least one of the biochemical or physiological effects exerted by the molecule. It is well-known in the art 15 that many enzymes and other effector molecules have an active site which is responsible for the effects exerted by the molecule in question. Other parts of the molecule may serve a stabilizing or solubility enhancing purpose and can therefore be left out if these purposes are not of relevance in the context 20 of a certain embodiment of the present invention.

The term "adjuvant" has its usual meaning in the art of vaccine technology, i.e. a substance or a composition of matter which is 1) not in itself capable of mounting a specific immune response against the immunogen of the vaccine, but which 25 is 2) nevertheless capable of enhancing the immune response against the immunogen. Or, in other words, vaccination with the adjuvant alone does not provide an immune response against the immunogen, vaccination with the immunogen may or may not give rise to an immune response against the immunogen, but the 30 combination of vaccination with immunogen and adjuvant induces 11 an immune response against the immunogen which is stronger than that induced by the immunogen alone.

"Targeting" of a molecule is in the present context intended to denote the situation where a molecule upon introduction in 5 the animal will appear preferentially in certain tissue(s) or will be preferentially associated with certain cells or cell types. The effect can be accomplished in a number of ways including formulation of the immunogen in a composition facilitating targeting or by introduction in the immunogen of groups 10 which facilitates targeting. These issues will be discussed in detail below.

"Stimulation of the immune system" means that a substance or composition of matter exhibits a general, non-specific immu-nostimulatory effect. A number of adjuvants and putative adju-15 vants (such as certain cytokines) share the ability to stimulate the immune system. The result of using an immunostimula-ting agent is an increased "alertness" of the immune system meaning that simultaneous or subsequent immunization with an immunogen induces a significantly more effective immune re-20 sponse compared to isolated use of the immunogen.

The term "polyhydroxypolymer carrier" is intended to denote the part of the immunogen that carries the amino acid sequences. As a general rule, the polyhydroxypolymer carrier has its outer limits where amino acid sequences can be cleaved of 25 by a peptidase, e.g. in an antigen presenting cell that is processing the immunogen. Hence, the polyhydroxypolymer carrier can be the polyhydroxypolymer with an activation group, where the bond between the activation group and the amino acid sequence is cleavable by a peptidase in an APC, or the polyhy-30 droxypolymer carrier can be a polyhydroxypolymer with activa P1015PC00 12 tion group and e.g. a linker such as a single L-amino acid or a number of D-amino acids, where the last part of the linker can bond to the amino acid sequences and be cleaved by a peptidase in an APC.

The term "polysaccharide" is intended to be used with its normal meaning, i.e. "a combination of nine or more monosaccharides, linked together by glycosidic bonds", cf. Hawley's Condensed Chemical Dictionary, 11th ed., Sax and Lewis, eds., Van Nostrand Reinhold Co., New York, 1987. Examples of such poly-10 saccharides are dextran (e.g. Dextran 40, Dextran 70, Dextran 75), agarose, cellulose and starch.

Unless the context clearly requires otherwise, throughout the description and the claims, the words "comprise", "comprising" and the like, are to be construed in an inclusive sense as 15 opposed to an exclusive or exhaustive sense, that is to say, in the sense of "including, but not limited to". 1st and 2n antigenic determinants The rationale behind the present invention is that the provi-20 sion of synthetic immunogens (especially peptide-containing immunogens) provides a greater deal of control over the composition of the end-product. In contrast, when using recombi-nantly produced polypeptide immunogens, purification and characterization is always a major task. Hence, in cases where 25 specific antigenic determinants (epitopes) can be identified that are suitable as the main constituent in an immunogen, the present invention provides for a convenient way of preparing the immunogens in a cost-effective manner.

IIIILLLLLIU^rnurtHiy OFFICE ] (Followed by page 12a) o k< NOV 2004 .RECEIVED P1015PC00 12a For most antigens, epitopes (both B-cell epitopes and CTL epitopes) are already known and published in the sci-entific literature - in practice a known protein may be "scanned" for epitopes by preparing overlapping truncates thereof that are 5 reacted with monoclonal antibodies raised against the protein. The fragments that react with the antibody constitute local epitopes. Other suitable technologies include those described in Irving MB et al., Curr Opin Chem Biol 2001 5(3):314-24, (Followed by page 13) 13 Parker CE and Tomer KB, Methods Mol Biol 2000;146:185-201, and Nelson PN et al., Mol Pathol 2000; 53(3):lll-7. Methods for prediction of epitopes are described in Nussinov R and Wolfson HJ, Comb Chem High Throughput Screen 1999;2(5):261-9 Further-5 more, methods of predicting and mapping the presence of epitopes (especially in protein antigens) via computer algorithms are also well-known in the art. For instance, CTL epitopes may be predicted via the methods described in Rothbard et al. EMBO J. 7:93-100 (1988) and in de Groot MS et al.r Vaccine 10 2001;19(31):4385-95 or otherwise identified via the technologies described in Rammensee H-G. et al. (1995), Immunogenetics 41: 178-228, Schirle M et al. Eur J Immunol 2000;30(18):2216-2225.

Hence, it is especially preferred that either or both of the 15 at least one first and second antigenic determinants of the immunogen are peptides, i.e. that they are constituted by amino acid sequences - since the 1st and 2nd amino acid sequences are normally attached separately to the activated polyhydroxypolymer carrier, their respective lengths can be 20 kept at a minimum, thus facilitating the synthesis steps for each peptide species. The length of such amino sequences are contemplated to range from about 4 amino acids to about 100 (even though there is no upper limit), but preferably the upper limit will not exceed 80 amino acids, and it is preferred 25 that the upper limit does not exceed 60 amino acids. Especially preferred lengths of peptidic antigenic determinants are thus in the range between about 4 to about 50 amino acids. Even lower upper limits are envisaged, such as at most 40, at most 30 and at most 25 amino acids. It is especially preferred 30 that a peptidic antigenic determinant is constituted by an amino acid sequence of 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acids. It 14 is also contemplated to utilise e.g. recombinantly produced polypeptides as the molecule constituting the 1st antigenic determinant and using synthetic peptides as the 2nd antigenic determinant. This would e.g. provide for conjugates where a 5 full-length self-polypeptide is coupled to the carrier and the Th epitopes are coupled in other positions. It should thereby be possible to attach the necessary TH epitopes (perhaps several species) to the same molecular entity, without substantially interfering with the 3D structure of the self-polypep-10 tide and thereby break tolerance.

In order to obtain processing and presentation of peptides of the immunogen by antigen presenting cells (APCs), the APCs must be able to cleave off the peptide antigenic determinant from the polyhydroxypolymer carrier. This is most conveniently 15 achieved by having such a peptide antigenic determinant coupled to the carrier via a bond that can be cleaved by a peptidase, such as the peptidases that are active in the APCs' processing of peptide sequences. This can e.g. be achieved by having the determinants coupled to the carrier by means of a 20 peptide bond or an amide bond. In preferred embodiments the antigenic determinant is bound to the carrier, where the antigenic determinant provides for the nitrogen atom of the amide or peptide bond - for peptidic antigenic determinants, this has the consequence that the peptide has a free carboxy termi-25 nus, an effect obtained when using a tresyl group as the activation group.

In many cases the 1st and 2nd antigenic determinants will be derived from different molecules, i.e. they are not found in the same molecule in nature. Further, it is normally also the case 30 that they are not derived from the same species. And, even though it is preferred that the 1st and 2nd antigenic determi nants are coupled independently to the activated polyhydroxypolymer it can be envisaged that they are e.g. fused to each other and coupled to the carrier at the terminus of the fusion product - this will be feasible when both antigenic determi-5 nants are relatively small (such as when the 1st antigenic determinant is a CTL epitope and the 2nd is a pure TH epitope) .

The 2nd antigenic determinant preferably includes an immunodominant Th epitope, that is, epitope which in the vaccinated individual gives rise to a significant immune response, but it 10 is a well-known fact that a TH epitope which is immunodominant in one individual is not necessarily immunodominant in another individual of the same species, even though it may be capable of binding MHC Class II molecules in the latter individual. However, normally it will suffice to utilise a peptide that 15 strongly binds to an MHC class II molecule.

With respect to the issues of particular considerations concerning immunodominance and MHC restriction of T helper epitopes, reference is made to e.g. WO 00/65058 and WO 00/20027 where thorough descriptions can be found.

The Th epitope being part of the 2nd antigenic determinant is preferably a promiscuous TH epitope. There exist a number of naturally occurring promiscuous T-cell epitopes which are active in a large proportion of individuals of an animal species or an animal population and these are preferably introduced in 25 the vaccine thereby reducing the need for a very large number of different modified 2nd antigenic determinants in the same vaccine immunogen or in the same vaccine composition.

The promiscuous epitope can according to the invention be a naturally occurring human TH epitope such as epitopes from 30 tetanus toxoid (e.g. the P2 and P30 epitopes, cf. SEQ ID NOs: 16 1 and 2, respectively), diphtheria toxoid, Influenza virus hemagluttinin (HA), and P. falciparum CS antigen.

Over the years a number of other promiscuous T-cell epitopes have been identified. Especially peptides capable of binding a 5 large proportion of HLA-DR molecules encoded by the different HLA-DR alleles have been identified and these are all possible T-cell epitopes to be introduced in modified CEA used according to the present invention. Cf. also the epitopes discussed in the following references which are hereby all incorporated 10 by reference herein: WO 98/23635 (Frazer IH et al., assigned to The University of Queensland); Southwood S et. al, 1998, J. Immunol. 160: 3363-3373; Sinigaglia F et al., 1988, Nature 336: 778-780; Rammensee HG et al., 1995, Immunogenetics 41: 4 178-228; Chicz RM et al., 1993, J. Exp. Med 178: 27-47; Hammer 15 J et al., 1993, Cell 74: 197-203; and Falk K et al., 1994, Immunogenetics 39: 230-242. The latter reference also deals with HLA-DQ and -DP ligands. All epitopes listed in these 5 references are relevant as candidate natural epitopes to be used in the present invention, as are epitopes which share common 20 motifs with these.

Alternatively, the epitope can be any artificial T-cell epitope which is capable of binding a large proportion of haplo-types. In this context the pan DR epitope peptides ("PADRE") described in WO 95/07707 and in the corresponding paper Alex-25 ander J et al., 1994, Immunity 1: 751-761 (both disclosures are incorporated by reference herein) are interesting candidates for epitopes to be used according to the present invention. It should be noted that the most effective PADRE peptides disclosed in these papers carry D-amino acids in the C-30 and N-termini in order to improve stability when administered. However, the present invention primarily aims at incorporating 17 the relevant epitopes as part of the immunogen which should then subsequently be broken down enzymatically inside the lysosomal compartment of APCs to allow subsequent presentation in the context of an MHC-II molecule and therefore it is not 5 expedient to incorporate D-amino acids in the epitopes used in the present invention.

One especially preferred PADRE peptide is the one having the amino acid sequence AKFVAAWTLKAAA (SEQ ID NO: 3) or an immunologically effective subsequence thereof. This, and other 10 epitopes having the same lack of MHC restriction are preferred T-cell epitopes that should be present in the modified CEA used in the inventive method. Such super-promiscuous epitopes will allow for the simplest embodiments of the invention wherein only one single modified CEA is presented to the vac-15 cinated animal's immune system.

Apart from the 1st and 2nd antigenic determinants, the immunogen of the invention may also contain other moieties that provide for desirable features of the immunogen. For instance, the immunogen may further comprise at least one moiety coupled to 20 the polyhydroxypolymer, said at least one moiety being selected from the group consisting of an immune stimulating moiety, a targeting moiety, or a presentation enhancing moiety -these are also discussed in detail below in connection with adjuvants. If such a moiety is a peptide it may be coupled to 25 the activated polyhydroxypolymer in the same step as the coupling of the 1st and 2nd antigenic determinants.

Hence, the immunogen of the invention can also include the introduction of a moiety which targets the immunogen to an APC or a B-lymphocyte. For instance, the first moiety can be a 30 specific binding partner for a B-lymphocyte specific surface 18 antigen or for an APC specific surface antigen. Many such specific surface antigens are known in the art. For instance, the moiety can be a carbohydrate for which there is a receptor on the B-lymphocyte or the APC (e.g. mannan or mannose). Alterna-5 tively, the second moiety can be a hapten. Also an antibody fragment which specifically recognizes a surface molecule on APCs or lymphocytes can be used as a first moiety (the surface molecule can e.g. be an FCy receptor of macrophages and monocytes, such as FCyRI or, alternatively any other specific sur-10 face marker such as CD40 or CTLA-4). It should be noted that all these exemplary targeting molecules can be used as part of an adjuvant, cf. below. CD40 ligand, antibodies against CD40, or variants thereof which bind CD40 will target the modified CEA to dendritic cells. At the same time, recent results have 15 shown that the interaction with the CD40 molecule renders the Th cells unessential for obtaining a CTL response. Hence, it is contemplated that the general use of CD40 binding molecules as the first moiety (or as adjuvants, cf. below) will enhance the CTL response considerably; in fact, the use of such CD40 bin-20 ding molecules as adjuvants and "first moieties" in the meaning of the present invention is believed to be inventive in its own right.

As an alternative or supplement to targeting the immunogen to a certain cell type in order to achieve an enhanced immune re-25 sponse, it is possible to increase the level of responsiveness of the immune system by including the an immune system stimulating moiety. Typical examples of such moieties are cytokines, heat-shock proteins, and hormones, as well as effective parts thereof.

Suitable cytokines to be used according to the invention are those which will normally also function as adjuvants in a vac 19 cine composition, e.g. interferon y (IFN-y), Flt3 ligand (Flt3L), interleukin 1 (IL-1), interleukin 2 (IL-2), interleu-kin 4 (IL-4), interleukin 6 (IL-6), interleukin 12 (IL-12), interleukin 13 (IL-13), interleukin 15 (IL-15), and granulo-5 cyte-macrophage colony stimulating factor (GM-CSF); alternatively, the functional part of the cytokine molecule may suffice as the second moiety. With respect to the use of such cytokines as adjuvant substances, cf. the discussion below.

Alternatively, the immune stimulating moiety can be a toxin, 10 such as listeriolycin (LLO), lipid A and heat-labile entero-toxin. Also, a number of mycobacterial derivatives such as MDP (muramyl dipeptide), CFA (complete Freund's adjuvant) and the trehalose diesters TDM and TDE are interesting possibilities.

According to the invention, suitable heat shock proteins used 15 as the immune stimulating moiety can be HSP70, HSP9Q, HSC70 (a heat shock cognate), GRP94, and calreticulin (CRT). Finally, CpG motifs and the immune stimulating peptide tuftsin are other possibilities.

Also the possibility of introducing a presentation enhancing 20 moiety is an important embodiment of the invention. The art has shown several examples of this principle. For instance, it is known that the palmitoyl lipidation anchor in the Borrelia burgdorferi protein OspA can be utilised so as to provide self-adjuvating polypeptides (cf. e.g. WO 96/40718). It seems 25 that the lipidated proteins form up micelle-like structures with a core consisting of the lipidation anchor parts of the polypeptides and the remaining parts of the molecule protruding therefrom, resulting in multiple presentations of the antigenic determinants. Hence, the use of this and related ap-30 proaches using different lipidation anchors (e.g. a myristyl group, a farnesyl group, a geranyl-geranyl group, a GPI-an-chor, and an N-acyl diglyceride group) are preferred embodiments of the invention, especially since the provision of such a lipidation anchor in a recombinantly produced protein is 5 fairly straightforward and merely requires use of e.g. a naturally occurring signal sequence as a fusion partner for a component of the immunogen. Another possibility is use of the C3d fragment of complement factor C3 or C3 itself (cf. Dempsey et al., 1996, Science 271, 348-350 and Lou & Kohler, 1998, Nature 10 Biotechnology 16, 458-462).

The polyhydroxypolymer carrier In order for amino acid sequences to couple to the polyhydroxypolymer it is normally necessary to "activate" the polyhydroxypolymer with a suitable reactive group that can form 15 the necessary link to the amino acid sequences.

The term "polyhydroxypolymer" is generally intended to have the same meaning as in WO 00/05316, i.e. the polyhydroxypolymer can have exactly the same characteristics as is specifically taught in that application. Hence, the polyhydroxypoly-20 mer can be water soluble or insoluble (thus requiring different synthesis steps during preparation of the immunogen).

Both embodiments given rise to certain advantages. In general, the coupling of peptides to a water-soluble activated polyhydroxypolymer is chemically simpler than the synthesis applica-25 ble for an insoluble polymer. It is also contemplated that induction of CTLs will be facilitated by using water-soluble carriers in the invention since such immunogens would be likely to be taken up via pinocytosis. On the other hand, the insoluble polymer can, when grinded, form a particulate compo-30 sition that is believed to be well-suited for inducing T~cell 21 help due to it being predominantly taken up by APCs and since it results in local concentration of antigen. It is therefore also within the scope of the present invention to utilise vaccination strategies where both water-soluble and water-insolu-5 ble immunogens are utilised.

In the event the polymer is dextran, water soluble forms are in general linear molecules, whereas the water insoluble forms of dextran are cross-linked.

The polyhydroxypolymer can be selected from naturally occur-10 ring polyhydroxy compounds and synthetic polyhydroxy compounds .

Specific and preferred polyhydroxypolymers are polysaccharides selected from acetan, amylopectin, gum agar-agar, agarose, alginates, gum Arabic, carregeenan, cellulose, cyclodextrins, 15 dextran, furcellaran, galactomannan, gelatin, ghatti, glucan, glycogen, guar, karaya, konjac/A, locust bean gum, mannan, pectin, psyllium, pullulan, starch, tamarine, tragacanth, xan-than, xylan, and xyloglucan. Dextran is especially preferred.

However, the polyhydroxypolymer can also be selected from 20 highly branched poly(ethyleneimine)(PEI), tetrathienylene vi-nylene, Kevlar (long chains of poly-paraphenyl terephtala-mide), Poly(urethanes), Poly(siloxanes), polydimethylsiloxane, silicone, Poly(methyl methacrylate) (PMMA), Poly(vinyl alcohol), Poly(vinyl pyrrolidone), Poly(2-hydroxymethylmethacry-25 late), Poly(N-vinyl pyrrolidone), Poly(vinyl alcohol), Poly(acrylic acid), Polytetrafluoroethylene (PTFE), Poly-acrylamide, Poly(ethylene-co-vinyl acetate), Poly(ethylene glycol) and derivatives, Poly(methacrylic acid), Polylactides (PLA), Polyglycolides (PGA), Poly(lactide-co-glycolides) 30 (PLGA), polyvinylalcohol, poly(hydroxymethylmethacrylate), 22 poly(hydroxyethylmethacrylate), poly(hydroxypropylmethacrylate)Polyanhydrides, and Polyor-thoesters, as well as corresponding copolymers.

The (weight) average molecular weight of the polyhydroxypoly-5 mer in question (i.e. before activation) is at least 500, typically at least 1,000, such as at least 2,000, preferably in the range of 2,500-2,000,000, more preferably in the range of 3,000-1,000,000, in particular in the range of 5,000-500,000. It is believed that polyhydroxypolymers having an av-10 erage molecular weight in the range of 10,000-200,000 are particularly advantageous.

When using a water-soluble polyhydroxypolymer, it is preferably water soluble to an extent of at least 10 mg/ml, preferably at least 25 mg/ml, such as at least 50 mg/ml, in particular at 15 least 100 mg/ml, such as at least 150 mg/ml at room temperature. It is known that dextran, even when activated as described herein, fulfils the requirements with respect to water solubility.

For some of the most interesting polyhydroxypolymers, the ra-20 tio between C (carbon atoms) and OH groups (hydroxy groups) of the unactivated polyhydroxypolymers (i.e. the native polyhydroxypolymer before activation) is in the range of 1.3 to 2.5, such as 1.5-2.3, preferably 1.6-2.1, in particular 1.85-2.05. Without being bound to any specific theory, it is believed 25 that such as a C/OH ratio of the unactivated polyhydroxypolymer represents a highly advantageous level of hydrophilicity. Polyvinylalcohol and polysaccharides are examples of polyhydroxypolymers which fulfil this requirement. It is believed that the above-mentioned ratio should be roughly the same for 23 the activated polyhydroxypolymer as the activation ratio should be rather low.

As mentioned above, the polyhydroxypolymers carry functional groups (activation groups), which facilitates the anchoring of 5 peptides to the carrier. A wide range of applicable functional groups are known in the art, e.g. tresyl (trifluoroethylsul-phonyl), maleimido, p-nitrophenyl cloroformate, cyanogenbro-mide, tosyl (p-toluenesulfonyl), triflyl (trifluoromethanesul-fonyl), pentafluorobenzenesulfonyl, and vinyl sulphone groups. 10 Preferred examples of functional groups within the present invention are tresyl, maleimido, tosyl, triflyl, pentafluorobenzenesulfonyl, p-nitrophenyl cloroformate, and vinylsulphone groups, among which tresyl, maleimido, and tosyl groups are particularly relevant.

Tresyl activated polyhydroxypolymers can be prepared using tresyl chloride as described for activation of dextran in Example 1 in WO 00/05316 or as described in Gregorius et al., J. Immunol. Meth. 181 (1995)' 65-73.

Maleimido activated polyhydroxypolymers can be prepared using 20 p-maleimidophenyl isocyanate as described for activation of dextran in Example 3 of WO 00/05316. Alternatively, maleimido groups could be introduced to a polyhydroxypolymer, such as dextran, by derivatisation of a tresyl activated polyhydroxypolymer (such as tresyl activated dextran (TAD)) with a dia-25 mine compound (generally H2N-CnH2n-NH2, where n is 1-20, preferably 1-8), e.g. 1,3-diaminopropane, in excess and subsequently react the amino groups introduced in TAD with reagents such as succinimidyl 4-(N-maleimidomethyl)cyclohexane-l-car-boxylate (SMCC), sulfo-succinimidyl 4-(N-maleimidomethyl)-30 cyclohexane-l-carboxylate (sulfo-SMCC), succinimidyl 4-(p- 24 maleimidophenyl)butyrate (SMPB), sulfo-succinimidyl 4-(p-maleimidophenyl)butyrate (sulfo-SMPB), N-y-maleimidobutyryloxy-succinimide ester (GMBS) or N-y-maleimidobutyryloxy-sulfosuc-cinimide ester. Although the different reagents and routes 5 for activation formally results in slightly different malei-mide activated products with respect to the linkage between the maleimide functionality and the remainder of the parent hydroxy group on which activation is performed, all and every are considered as "maleimide activated polyhydroxypolymers".

Tosyl activated polyhydroxypolymers can be prepared using tosyl chloride as described for activation of dextran in Example 2 in WO 00/05316. Triflyl and pentafluorobenzenesulfonyl activated polyhydroxypolymers are prepared as the tosyl or tresyl activated analogues, e.g. by using the corresponding acid 15 chlorides.

Cyanogenbromide activated polyhydroxypolymer can be prepared by reacting the polyhydroxypolymer with cyanogenbromide using conventional methods. The resulting functional groups are normally cyanate esters with two hydroxy groups of the polyhy-20 droxypolymer.

The degree of activation can be expressed as the ratio between the free hydroxy groups and the activation groups (i.e. func-tionalised hydroxy groups). It is believed that a ratio between the free hydroxy groups of the polyhydroxypolymer and 25 the activation groups should be between 250:1 and 4:1 in order to obtain an advantageous balance between the hydrophilicity and the reactivity of the polyhydroxypolymer. Preferably the ratio is between 100:1 and 6:1, more preferably between 60:1 and 8:1, in particular between 40:1 and 10:1.

Especially interesting activated polyhydroxypolymers for use in the method for producing the generally applicable immunogen according to the invention are tresyl, tosyl and maleimido activated polysaccharides, especially tresyl activated dextran 5 (TAD), tosyl activated dextran (TosAD), and maleimido activated dextran (MAD).

The polyhydroxypolymer carrier may be substantially free of amino acid residues, necessitating that the activation group provides for part of a peptidase cleavable bond since the an-10 tigenic determinant would not otherwise be able to enter the antigen processing steps of the APC's metabolism. However, as mentioned, the carrier may also simply include a spacer including at least one L-amino acid. Nevertheless, the at least first and at least second antigenic determinants are normally 15 bound to the activated version of the polyhydroxypolymer via a nitrogen, preferably at the N-terminus of an amino acid sequence .

In brief, in the preferred embodiments of the invention where either of the antigenic determinants may be a peptide, the ac-20 tivated polyhydroxypolymer must normally contain at least one amino acid group if the bond between an amino acid and the activation group cannot be broken by the APC's biochemical machinery. The at least one amino acid group(s) then serves as spacer(s) between the activation group and the antigenic pep-25 tide determinant, with the consequence that the bond between the carrier's amino acid(s) and the peptide determinant may be cleaved, leaving the peptide free for attack by peptidases of the APCs processing pathway. Of course, the binding between an activation group and a peptide determinant need not be sen-30 sitive to peptidase cleavage - it may equally well be sensitive to other physicochemical conditions that are found in the 26 APC. The important goal to achieve is that the antigenic determinant is liberated inside the APC, thus allowing for binding to an MHC molecule and subsequent presentation to lymphocytes .

Preparation of immunogen of the invention When using the preferred peptide determinants, it is possible to synthesise the peptides so as to protect all available amino groups but the one at the N-terminus, subsequently couple the resulting protected peptides to the activated polyhy-10 droxypolymer moiety, and finally de-protecting the resulting conjugate. A specific example of this approach is described in the examples below - it will, however, be appreciated by the skilled person in peptide chemistry, that multiple methods for obtaining this effect may be employed.

Instead of using the water-soluble polysaccharide molecules as taught in WO 00/05316 and US 5,874,469, it is, as mentioned above, equally possible to utilise cross-linked polysaccharide molecules, thereby obtaining a particulate conjugate between polypeptides and polysaccharide - this is believed to lead to 20 an improved presentation to the immune system of the polypeptides, since two goals are reached, namely to obtain a local deposit effect when injecting the conjugate and to obtain particles which are attractive targets for uptake by APCs. The approach of using such particulate systems is also detailed in 25 the examples, but in general the activated polyhydroxy polymer is used to combine the antigenic determinants containing the B-cell epitope and the T-helper epitopes it can, as mentioned above be performed as a solid phase synthesis and the final product can be harvested and purified by wash and filtration. 30 The elements to be coupled to an activated polyhydroxypolymer 27 (peptides, tags etc) can be added to the polyhydroxypolymer at low pH, e.g. pH 4-5, and allowed to be equally distributed in the "gel" by passive diffusion. Subsequently, the pH can be raised to pH 9-10 to start the reaction of the primary amino 5 groups on the peptides and tags to the tresyl groups on the polyhydroxy polymer. After coupling of peptides and e.g. immune stimulating elements or targeting moieties the gel is grinded to form particles of suitable size for immunization.

The ratio of B-cell epitopes and T-helper epitopes (P2, P30, 10 PADRE or other suitable epitopes) in the final product can be varied by varying the concentration of these molecules in the synthesis step. As mentioned above, the immunogenic molecule can be tagged with e.g. mannose, tuftsin, CpG-motifs or other immune stimulating substances (described herein) by adding 15 these, if necessary by using e.g. aminated derivatives of the substances, to the carbonate buffer in the synthesis step.

Vaccine and other immunizing formulations When administration of the immunogens of the invention to an animal such as a human being, the formulation of the immunogen 20 follows the principles generally acknowledged in the art. In the following is given a detailed description relevant for peptide vaccines and immunizing compositions since peptides constitute the most preferred embodiments of the above-mentioned 1st and 2nd antigenic determinants. The skilled reader 25 will, though, appreciate that the general principles given below also will be applicable for most, if not all, vaccine strategies that include an immunogen of the invention.

Preparation of vaccines and immunizing agents that contain peptide sequences as active ingredients is generally well un-30 derstood in the art, as exemplified by U.S. Patents 4,608,251; 28 4,601,903; 4,599,231; 4,599,230; 4,596,792; and 4,578,770, all incorporated herein by reference. Typically, such vaccines are prepared as injectables either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, 5 liquid prior to injection may also be prepared. The preparation may also be emulsified. The active immunogenic ingredient is often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, gly-10 cerol, ethanol, or the like, and combinations thereof. In addition, if desired, the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, or adjuvants which enhance the effectiveness of the vaccines; cf. the detailed discussion of adjuvants be-15 low.

The vaccines are conventionally administered parenterally, by injection, for example, either subcutaneously, intracutane-ously, or intramuscularly. Additional formulations which are suitable for other modes of administration include supposito-20 ries and, in some cases, oral, buccal, sublinqual, intraperitoneal, intravaginal, anal, epidural, spinal, and intracranial formulations. For suppositories, traditional binders and carriers may include, for example, polyalkalene glycols or triglycerides; such suppositories may be formed from mixtures 25 containing the active ingredient in the range of 0.5% to 10%, preferably 1-2%. Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like. These com-30 positions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10-95% of active ingredient, preferably 25-70%. For 29 oral formulations, cholera toxin is an interesting formulation partner (and also a possible conjugation partner).

The immunogens may be formulated into the vaccine as neutral or salt forms. Pharmaceutically acceptable salts include acid 5 addition salts (e.g. formed with the free amino groups of a peptide constituting part of an immunogen of the invention) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts 10 formed with free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, his-tidine, procaine, and the like.

The vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective and immunogenic. The quantity to be administered depends on the subject to be treated, including, e.g., the capacity of the individual's immune system to mount an im-20 mune response, and the degree of protection desired. Suitable dosage ranges are of the order of several hundred micrograms active ingredient per vaccination with a preferred range from about 0.1 pg to 2,000 pg (even though higher amounts in the 1-10 mg range are contemplated), such as in the range from about 25 0.5 pg to 1, 000 pg, preferably in the range from 1 pg to 500 pg and especially in the range from about 10 pg to 100 pg. Suitable regimens for initial administration and booster shots are also variable but are typified by an initial administration followed by subsequent inoculations or other administra-30 tions.

The manner of application may be varied widely. Any of the conventional methods for administration of a vaccine are applicable. These include oral application on a solid physiologically acceptable base or in a physiologically acceptable 5 dispersion, parenterally, by injection or the like. The dosage of the vaccine will depend on the route of administration and will vary according to the age of the person to be vaccinated and the formulation of the antigen.

Some of the immunogens of the vaccine are sufficiently immuno-10 genie in a vaccine, but for some of the others the immune response will be enhanced if the vaccine further comprises an adjuvant substance.

Various methods of achieving adjuvant effect for the vaccine are known. General principles and methods are detailed in "The 15 Theory and Practical Application of Adjuvants", 1995, Duncan E.S., Stewart-Tull (ed.), John Wiley & Sons Ltd, ISBN 0-471-95170-6, and also in "Vaccines: New Generation Immunological Adjuvants", 1995, Gregoriadis G et al. (eds.), Plenum Press, New York, ISBN 0-306-45283-9, both of which are hereby incor-20 porated by reference herein.

It is especially preferred to use an adjuvant which can be demonstrated to facilitate breaking of the autotolerance to self-protiens and other haptens that are not merely non-immu-nogenic due to their small size; however, in cases where the 25 antigenic determinants coupled to the polyhydroxy polymer are both sufficiently large and sufficiently immunogenic, the adjuvant need not be incorporated.

Non-limiting examples of suitable adjuvants are selected from the group consisting of an immune targeting adjuvant; an im-30 mune modulating adjuvant such as a toxin, a cytokine, and a 31 mycobacterial derivative; an oil formulation; a polymer; a micelle forming adjuvant; a saponin; an immunostimulating complex matrix (ISCOM matrix); a particle; DDA; aluminium adjuvants.; DNA adjuvants; y-inulin; and an encapsulating adjuvant.

In general it should be noted that the disclosures above which relate to compounds and agents useful as moieties in the immunogens also refer mutatis mutandis to their use in the adjuvant of a vaccine of the invention - in other words, instead of being part of the immunogen of the invention, such moieties 10 are also suited as parts of the formulations of the present invention.

The application of adjuvants include use of agents such as aluminium hydroxide or phosphate (alum), commonly used as 0.05 to 0.1 percent solution in buffered saline, admixture with 15 synthetic polymers of sugars (e.g. Carbopol®) used as 0.25 percent solution, aggregation of protein in the vaccine by heat treatment with temperatures ranging between 70° to 101°C for 30 second to 2 minute periods respectively and also aggregation by means of cross-linking agents are possible. Aggrega-20 tion by reactivation with pepsin treated antibodies (Fab fragments) to albumin, mixture with bacterial cells such as C. parvum or endotoxins or lipopolysaccharide components of gram-negative bacteria, emulsion in physiologically acceptable oil vehicles such as mannide mono-oleate (Aracel A) or emulsion 25 with 20 percent solution of a perfluorocarbon (Fluosol-DA) used as a block substitute may also be employed. Admixture with oils such as squalene and IFA is also preferred.

According to the invention DDA (dimethyldioctadecylammonium bromide) is an interesting candidate for an adjuvant as is DNA 30 and y-inulin, but also Freund's complete and incomplete adjuvants as well as guillaja saponins such as QuilA and QS21 are 32 interesting as is RIBI. Further possibilities are monophos-phoryl lipid A (MPL), the above mentioned C3 and C3d, and mu-ramyl dipeptide (MDP).

Liposome formulations are also known to confer adjuvant ef-5 fects, and therefore liposome adjuvants are preferred according to the invention.

Also immunostimulating complex matrix type (ISCOM® matrix) adjuvants are preferred choices according to the invention, es-pecially since it has been shown that this type of adjuvants 10 are capable of up-regulating MHC Class II expression by APCs. An ISCOM® matrix consists of (optionally fractionated) saponins (triterpenoids) from Quillaja saponaria, cholesterol, and phospholipid. When admixed with the immunogenic protein, the resulting particulate formulation is what is known as an ISCOM 15 particle where the saponin constitutes 60-70% w/w, the cholesterol and phospholipid 10-15% w/w, and the protein 10-15% w/w. Details relating to composition and use of immunostimulating complexes can e.g. be found in the above-mentioned text-books dealing with adjuvants, but also Morein B et al., 1995, Clin. 20 Immunother. 3: 461-475 as well as Barr IG and Mitchell GF, 1996, Immunol, and Cell Biol. 74: 8-25 (both incorporated by reference herein) provide useful instructions for the preparation of complete immunostimulating complexes.

Another highly interesting (and thus, preferred) possibility 25 of achieving adjuvant effect is to employ the technique described in Gosselin et al., 1992 (which is hereby incorporated by reference herein). In brief, the presentation of a relevant antigen such as an antigen of the present invention can be enhanced by conjugating the antigen to antibodies (or antigen 30 binding antibody fragments) against the Fey receptors on mono- 33 cytes/macrophages. Especially conjugates between antigen and anti-FcyRI have been demonstrated to enhance immunogenicity for the purposes of vaccination.

Other possibilities involve the use of the targeting and im-5 mune modulating substances (i.a. cytokines) mentioned in the claims as moieties for the protein constructs. In this connection, also synthetic inducers of cytokines like poly I:C are possibilities.

Suitable mycobacterial derivatives are selected from the group 10 consisting of muramyl dipeptide, complete Freund's adjuvant, RIBI, and a diester of trehalose such as TDM and TDE.

Suitable immune targeting adjuvants are selected from the group consisting of CD40 ligand and CD40 antibodies or specifically binding fragments thereof (cf. the discussion 15 above), mannose, a Fab fragment, and CTLA-4.

Suitable polymer adjuvants are selected from the group consisting of a carbohydrate such as dextran, PEG, starch, man-nan, and mannose; a plastic polymer; and latex such as latex beads.

Yet another interesting way of modulating an immune response is to include the immunogen (optionally together with adjuvants and pharmaceutically acceptable carriers and vehicles) in a "virtual lymph node" (VLN) (a proprietary medical device developed by ImmunoTherapy, Inc., 360 Lexington Avenue, New 25 York, NY 10017-6501). The VLN (a thin tubular device) mimics the structure and function of a lymph node. Insertion of a VLN under the skin creates a site of sterile inflammation with an upsurge of cytokines and chemokines. T- and B-cells as well as APCs rapidly respond to the danger signals, home to the in 34 flamed site and accumulate inside the porous matrix of the VLN. It has been shown that the necessary antigen dose required to mount an immune response to an antigen is reduced when using the VLN and that immune protection conferred by 5 vaccination using a VLN surpassed conventional immunization using Ribi as an adjuvant. The technology is i.a. described briefly in Gelber C et al., 1998, "Elicitation of Robust Cellular and Humoral Immune Responses to Small Amounts of Immunogens Using a Novel Medical Device Designated the Virtual Lymph 10 Node", in: "From the Laboratory to the. Clinic, Book of Abstracts, October 12th - 15th 1998, Seascape Resort, Aptos, California" .

It is expected that the vaccine of the invention should be administered at least once a year, such as at least 1, 2, 3, 4, 15 5, 6, and 12 times a year. More specifically, 1-12 times per year is expected, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 times a year to an individual in need thereof. It has previously been shown that the memory immunity induced by the use of the preferred autovaccines according to the invention 20 is not permanent, and therefor the immune system needs to be periodically challenged with the analogues.

Due to genetic variation, different individuals may react with immune responses of varying strength to the same polypeptide. Therefore, the vaccine according to the invention may comprise 25 several different immunogens with differences in the choice of antigenic determinants in order to increase the immune response, cf. also the discussion above concerning the choice of foreign T-cell epitope introductions. The vaccine may comprise two or more immunogens, where all of the immunogens are as de-30 fined above.

The vaccine may consequently comprise 3-20 different immunogens of the invention, such as 3-10 immunogens. However, normally the number of analogues will be sought kept to a minimum such as 1 or 2 analogues, especially because the immunogens 5 may be tailored to include both the necessary 1st antigenic determinants and the necessary 2nd antigenic determinants in order to target as large a fraction of the vaccinated population.

Identifying useful immunogens As mentioned above, an advantage of the immunogens of the invention is that they can be tailored to provide the optimum ratio between 1st and 2nd antigenic determinants. This also allows for the provision of a method for selection and preparation of useful immunogens of the invention. The method entails 15 preparation of at least two different immunogens of the invention where each different immunogen has a characteristic ratio between the 1st and 2nd antigenic determinants. These immunogens are then formulated as immunizing agents (cf. example 3) and their respective capabilities of inducing a specific immune 20 response against the 1st antigenic determinant are determined. The most effective immunogen(s) is/are selected and used for further development.

A similar approach can be used when determining the precise relative amount of targeting or immunostimulating moieties 25 that should be incorporated in the immunogens of the invention in order to obtain the best efficacy.

The 1st and 2nd antigenic determinants as well as possible further moieties are coupled to the activated polyhydroxypolymer essentially as described in the present examples. And since 30 the ratio of incorporated molecules in the immunogen is de 36 pendent on the relative concentrations of the molecules in the incubation mixture, it is unproblematic to prepare a large number of different immunogens merely be adjusting the relative concentrations of the molecules.

The present invention will now be illustrated by means of the following non-limiting examples.

EXAMPLE 1 Synthesis of an AJ3 Peptide Copolymer Vaccine using activated poly-hydroxypolymer as the cross-linking agent.

Introduction. A traditional conjugate vaccine consists of an antigen or hapten (e.g. in the form of a polypeptide antigen or hapten) coupled covalently to a carrier, such as a carrier protein. The antigen/hapten contains the B-cell or CTL epitope (s) and the carrier protein provides TH epitopes. However, 15 most of the carrier protein will normally be irrelevant as a source for TH epitopes, since only a minor part of the total sequence contains the relevant TH epitopes. Such epitopes can be defined and synthesized as peptides of e.g. 9-15 amino a-cids. If these peptides are linked covalently to peptides con-20 taining the B-cell or CTL epitopes, e.g. via a multivalent activated polyhydroxypolymer as taught herein, a vaccine molecule that only contains the relevant parts of the antigen and the traditional carrier can be obtained. It is further possible to provide an immunogen that contains an optimized compo-25 sition of B-cell epitopes, CTL epitopes, and TH epitopes.

Synthesis of the activated poly-hydroxypolymer. Polyhydroxypolymers such as dextran, starch, agarose etc. can be activated with 2,2,2-trifluoroethanesulfonyl chloride (tresyl 37 chloride), either by means of a homogenous synthesis (dextran) dissolved in N-methylpyrrolidinone (NMP) or by means of a heterogeneous synthesis (starch, agarose, cross-linked dextran) in e.g. acetone. 225 ml dry N-methyl pyrrolidinone (NMP) is added under dry conditions to freeze dried, water-soluble dextran (4.5 g, 83 mmol, clinical grade, Mw(avg) 78000) in a 500 ml round bottom flask supplied with a magnet for stirring. The flask is placed in a 60°C oil bath with magnetic stirring. The temperature is 10 raised to 92°C over a period of 20 min. When the dextran is dissolved the flask is immediately removed from the oil bath and the temperature in the bath is lowered to 40°C. The flask is placed into the oil bath agaom, still with magnetic stirring, and tresyl chloride (2.7 64 ml, 25 mmol) is added drop-15 wise. After 15 min, dry pyridine (anhydrous, 2.020 ml, 25 mmol) is added drop-wise. The flask is removed from the oil bath and stirred for 1 hour at room temperature. The product (Tresyl Activated Dextran, TAD) is precipitated in 1200 ml cold ethanol (99.9%). The supernatant is decanted and the precipitate is 20 harvested in 50 ml polypropylene tubes in a centrifuge at 2000 rpm. The precipitate is dissolved in 50 ml 0.5% acetic acid, dialyzed 2 times against 5000 ml 0.5% acetic acid and freeze-dried. TAD can be stored as a freeze-dried powder at -20°C.

Alternatively, an insoluble poly-hydroxypolymer, such as aga-25 rose or cross-linked dextran can be tresyl activated by making a suspension of the poly-hydroxypolymer in e.g. acetone and perform the synthesis as a solid phase synthesis. The activated poly-hydroxypolymer can be harvested by filtration. Suitable methods are reported in e.g. Nilsson K and Mosbach K 30 (1987), Methods in Enzymology 135, p. 67, and in Hermansson GT yjxJ&..; <kJ^aULjylU»,-*,« ■ v ^ \Li.. i.--^LasA^s^*;u-W^u*.

O 'J AlH f <- •-'. 'jo. r:j:.:2 38 s.\ S*V et al. (1992), in ""Immobilized Affinity Ligand Techniques", Academic Press, Inc., p. 87.

Synthesis of the immunogens of the invention - human A0-42 as an exemplary peptide antigen. TAD (10 mg) is dissolved in 100 5 jxl H20 and 1000 jil carbonate buffer, pH 9.6, containing 5 mg Ap-42 K0EQ ID HOi 2, rooiduoo -073 711^1, 2.5 mg P2 (SEQ 'ID NO: 1) and 2.5 mg P30 (SEQ ID NO: 2) is added. The AJ3-42 and the P2 and P30 peptides all contain protected lysine groups: these are in the form of 1-(4,4-Dimethyl-2, 6-dioxocyclohex-l-10 ylidene)ethyl (Dde) protected lysine groups.!The peptides are prepared by means of a standard Fmoc strategy, where the conventional Fmoc-Lys(Boc)-OH has been substituted with Fmoc-Lys(Dde)-OH (obtained from Novabiochem , cat. no. 04-12rll21), i.e. the e-amino group in lysine is protected with Dde instead 15 of Boc.

The pH value is measured and adjusted to 9.6 using 1 M H.C1.-After 2.5 hours at room temperature, hydrazine from an 80% solution is added to a final hydrazine concentration of 8% and the solution is incubated for another 30 min. at room .tempera-20 ture and freeze-dried immediately thereafter. The freeze-dried product is dissolved in H20 and dialysed extensively against H20 before the final freeze-drying.

The ratio between B-cell epitopes (Ap) and T-helper epitopes (P2 and P30) in the final product is varied using different 25 concentrations of these peptides in the synthesis step. .Furthermore, the final product can be tagged with e.g. mannose (so as to target the conjugate to APCs) by adding aminated mannose to the carbonate buffer in the synthesis step. , AMENDED SHEET 39 If an insoluble activated poly-hydroxypolymer is used to combine the peptides containing the B-cell epitope and the T-helper epitopes, the coupling to the polymer can be performed as a traditional solid phase synthesis and the final 5 product is harvested and purified by wash and filtration.

As mentioned in the general description, the presently described approach for preparing a peptide based vaccine may be applied to any other polypeptide antigen where it would be convenient to prepare a purely synthetic peptide vaccine and 10 where the polypeptide antigen in question provides sufficient immunogenicity in one single peptide: EXAMPLE 2 General Synthesis Peptide Copolymer Vaccines TAD (10 mg) is dissolved in 100 }xl H2O and 1000 pi carbonate 15 buffer, pH 9.6, containing 1-5 mg peptide A (any immunogenic peptide of interest), 1-5 mg P2 (diphtheria toxoid P2 epitope) and 1-5 mg P30 (diphtheria toxoid P30 epitope) is added. The pH value is measured and adjusted to 9.6 using 0.1 M HC1. After 2.5 hours at room temperature the solution is freeze dried 20 immediately hereafter. The freeze-dried product is dissolved in H2O and dialysed extensively against H2O or desalted on a gelfiltration column before the final freeze-drying. In case the peptides have lysine in the sequence the s-amine in the lysine side chain should be protected by Dde using the Fmoc-25 Lys(Dde)-OH derivative in the synthesis (Gregorius and Theisen 2001, submitted). After coupling, hydrazine from an 80% solution is added to a final hydrazine concentration between 1-20% and the solution is incubated for another 30 min at room temperature, freeze dried immediately hereafter and dialysed ex- WO 02/066056 PCT/DK02/00112 40 tensively against H2O or desalted on a gelfiltration column before the final freeze-drying. The principle is set forth in schematic form in Fig. 2.

Such immunogens have been utilised by the inventors with the 5 short 8 amino acid C-terminal fragment of the Borrelia burgdorferi protein OspC as "peptide A" and a diptheria toxoid epitope (P2 or P30) as peptide B. The results of immunization studies with this antigen revealed that only the immunogen of the invention including the OspC fragment and a foreign dipth-10 eria epitope matching the MHC haplotype of the vaccinated mice were capable of inducing antibodies reactive with OspC in these mice. In contrast, a molecule containing only the OspC peptide was unable to induce antibody production and the same was true for a mixture of 2 immunogens where one contained the 15 OspC and the other the epitope. It is therefore concluded that the inclusion in the same polyhydroxypolymer carrier is superior, if not essential, in order to induce antibody production against a short peptide hapten as OspC.

The above referenced experiment with the C-terminal OspC frag-20 ment has also demonstrated that coupling of peptides to TAD provides for an immunogen that is capable of triggering Th lymphocytes that provide specific T-cell help. This means that the immunogen is 1) capable of being taken up by APCs and 2) that the APCs are subsequently capable of processing the immu-25 nogen so as to present the TH epitopes in an MHC Class II context to TH lymphocytes. To the best of the present inventors' beliefs, the capacity of a polyhydroxypolymer to accomplish this effect has never been demonstrated previously. 41 EXAMPLE 3 Vaccination and efficacy determination Vaccinations The immunogen of the invention is injected into a suitable 5 animal species such as mouse, rat, guinea pig, rabbit, or monkey.

The immunogens can be mixed with a suitable adjuvant such as for example Freund's Adjuvant, ISA-51, aluminum-based adjuvants (aluminium phosphate or aluminium hydroxide, e.g. from 10 Danfoss), Calcium Phosphate, QS21 (Antigenics), MF59 (Chiron Corp.), and Ribi (Glaxo SmithKline). Protein vaccines are usually administered 3-5 times, for example at weeks 0, 3, 6, 9, 12.

Antibody titer determination Sera from vaccinated animals can be tested for specific antibodies by ELISA. 96-well Maxisorb plates (e.g obtained from Nunc, Life Technologies, Taastrup, Denmark) can be coated with a suitable volume (e.g. 50 ul) of either the antigen from which the 1st antigenic determinant is derived or with the an-20 tigenic determinant as such. This is done in a suitable buffer such as carbonate buffer pH 9.6 in a suitable concentration giving a final content of e.g. 1 ug/well. The plates are incubated, e.g. for 1 hour, washed in washing buffer, e.g. PBS + 0.5M NaCl + 1% Triton X-100 and then blocked for e.g. 1 hour 25 in dilution buffer that could e.g. be washing buffer plus 1% BSA. Standards and diluted serum samples can be added in duplicate and incubated in the plates, e.g. for 30 minutes. After washing, a dilution of secondary antibody (e.g. HRP conju 42 gated rabbit~anti-mouse IgG e.g. from DAKO, Glostrup, Denmark) can be added (e.g diluted 1:1000 in dilution buffer) and incubated for 30 minutes. The plates can then be washed in washing buffer, and a chromogenic substrate, e.g. OPD substrate (e.g. from Sigma-Aldrich, Vallensbeek Strand, Denmark) can be added. The reaction can be stopped with e.g 2N H2SO4 and the optical density be measured in e.g. a Dynex MRX ELISA plate reader at 490nm. Serum antibody concentrations can be calculated e.g. by relating the optical densities of the samples to a standard 10 curve. In general, there are many antibodies available from commercial or academic sources - these antibodies can be used to generate a standard curve, but in the event such an antibody should not be available, it can be prepared by methods known in the art.

The ELISA can be modified for different purposes. Sandwich ELISA can be used to monitor whether the antisera contains reactivities that can displace e.g. a biotin-labeled, therapeutically relevant antibody from binding to plate-coated antigen or 1st antigenic determinant. Specialized ELISA kits can be 20 used to determine the isotype subclass distribution in antisera etc.

Assays to monitor anti-CEA CTL activity It can be investigated whether immunization with CTL epitope containing vaccines can induce an antigen-specific CTL re-25 sponse. The CTL epitopes used in the immunogen can be used to pulse APCs in e.g. typical cytotoxic T cell assays. Antigen-expressing target cells (e.g. MHC class I expressing cell lines transfected with a gene encoding the antigen of interes) can be used as targets for antigen-specific cytotoxic T lym-30 phocytes (CTLs). Mice will be vaccinated with the inventive 43 immunogens using an appropriate vaccination scheme, cf. above. As positive control, mice could be immunized with e.g. MHC class I peptides derived from the antigen sequence. After a suitable time interval, e.g. three weeks after the first immu-5 nization, splenocytes from immunized mice can be re-stimulated e.g. with mytomicin C-treated (e.g. 50 jag/ml, 20 min at 37 °C) syngeneic splenocytes loaded with the peptides. For this re-stimulation process, a suitable number (e.g. 100x10s) of pep-tide-loaded syngeneic splenocytes can be mixed with a suitable 10 number (e.g. 60xl06) of splenocytes from vaccinated mice in and incubated at 37 °C for e.g. 7 days. After the restimulation process, the cytotoxic activity of the effector cells can be monitored e.g. in a chromium release assay. A suitable number (e.g. 5xl06) of target cells is labeled with 51Chromium (e.g. 15 200 mCi), if necessary loaded with antigen-derived peptide, and used as targets in a 51Chromium release assay. Cell lines transfected with the relevant antigen can also be used as targets for CTLs. Such CTL assays can e.g. be performed in normal wild type mice, transgenic mice and/or mice transgenic for hu-20 man HLA class I molecules (e.g. HHD mice) using suitable compatible target cells and cells for restimulation.

The ability of a vaccine of the invention to induce antigen-specific CTL responses can also be measured using other assay methods including antigen-specific tetramer stainings and 25 Elispot assays; all such methods are well-known to the person skilled in immunology. 44

Claims

1. An immunogen which comprises 5 a) at least one first antigenic determinant constituted by an amino acid sequence that includes at least one B-cell epitope and/or at least one CTL epitope, and b) at least one second antigenic determinant constituted by an amino acid sequence that includes a T helper cell epitope (TH epitope), 10 wherein each of the at least one first and second antigenic determinants are independently coupled through the nitrogen atoms at their respective N-termini to a pharmaceutically acceptable activated polyhydroxypolymer carrier via a bond that is cleavable by a peptidase. 15

2. The immunogen according to claim 1, wherein the at least first and at least second antigenic determinants are coupled to the activated polyhydroxypolymer carrier via an amide bond or a peptide bond.

3. The immunogen according to claim 2, wherein the at least 20 first and at least second antigenic determinants each provide for the nitrogen moiety of their respective bond.

4. The immunogen according to any one of the preceding claims, wherein the polyhydroxypolymer carrier is substantially free of amino acid residues. 25

5. The immunogen according to any of one of the preceding claims wherein the polyhydroxypolymer is water soluble. INTELLECTUAL PROPERTY OFFICE OF N.Z. 0 * MOV 20 RECEIVED 45

6. The immunogen according to any one of claims 1-4 wherein the polyhydroxypolymer is water insoluble.

7. The immunogen according to any one of the preceding claims, wherein the polyhydroxypolymer is selected from naturally 5 occurring polyhydroxy compounds and synthetic polyhydroxy compounds.

8. The immunogen according to any one of the preceding claims, wherein the polyhydroxypolymer is a polysaccharide selected from acetan, amylopectin, gum agar-agar, agarose, alginates, 10 gum Arabic, carregeenan, cellulose, cyclodextrins, dextran, furcellaran, galactomannan, gelatin, ghatti, glucan, glycogen, guar, karaya, konjac/A, locust bean gum, mannan, pectin, psyllium, pullulan, starch, tamarine, tragacanth, xanthan, xylan, and xyloglucan. 15

9. The immunogen according to claim 8, wherein the polyhydroxypolymer is dextran.

10. The immunogen according to any one claims 1-7, wherein the polyhydroxypolymer is selected from highly branched poly(ethyleneimine)(PEI), tetrathienylene vinylene, Kevlar 20 (long chains of poly-paraphenyl terephtalamide), Poly(urethanes), Poly(siloxanes), polydimethylsiloxane, silicone, Poly(methyl methacrylate) (PMMA), Poly(vinyl alcohol), Poly(vinyl pyrrolidone), Poly(2-hydroxy ethyl methacrylate), Poly(N-vinyl pyrrolidone), Poly(vinyl alcohol), Poly(acrylic 25 acid), Polytetrafluoroethylene (PTFE), Polyacrylamide, Poly(ethylene-co-vinyl acetate), Poly(ethylene glycol) and derivatives, Poly(methacrylic acid), Polylactides (PLA), Poly-glycolides (PGA), Poly(lactide-co-glycolides) (PLGA), Polyan-hydrides, and Polyorthoesters. MMltLLtCTUAL PROPERTY OFFICE OF N.Z. 0 4 nuv ium RECEIVED 46

11. The immunogen according to any of the preceding claims, wherein the average molecular weight of the polyhydroxypolymer before activation is at least 500.

12. The immunogen according to any one of the preceding 5 claims, wherein the polyhydroxypolymer is activated with functional groups selected from tresyl (trifluoroethylsulphonyl), maleimido, p-nitrophenyl cloroformate, and tosyl (p-toluene-sulfonyl).

13. The immunogen according to any of the preceding claims 10 that further comprises that at least one moiety is coupled to the polyhydroxypolymer, said at least one moiety being selected from the group consisting of an immune stimulating moiety or a targeting moiety.

14. The immunogen according to claim 13, wherein the at least 15 one moiety is a peptide.

15. The immunogen according to any of the preceding claims which is capable of being taken up by an antigen presenting cell (APC).

16. The immunogen according to claim 15, which is capable of 20 being processed by the APC whereby the APC presents the TH epitope on its surface bound to an MHC Class II molecule.

17. The immunogen according to any one of the preceding claims wherein the at least one first and second antigenic determinants are not derived from the same naturally occurring mole- 25 cule.

18. The immunogen according to claim 17, wherein the at least one and the at least second antigenic determinants do not occur naturally in the same species. INTELLECTUAL PROPERTY OFFICE OF N.Z. (H NOV 2004 RECEIVED 47

19. The immunogen according to any one of the preceding claims, wherein the TH epitope binds strongly to at least one human MHC Class II molecule.

20. The immunogen according to claim 19, wherein the TH 5 epitope is a promiscuous TH epitope in humans.

21. An immunogenic composition for raising an immune response against an antigen in a mammal, including a human being, comprising the immunogen according to any one of the preceding claims in admixture with a pharmacologically an immunologi- 10 cally acceptable carrier, excipient or diluent, and optionally with an adjuvant.

22. The immunogenic composition according to claim 21, wherein the adjuvant is selected from the group consisting of an immune targeting adjuvant; an immune modulating adjuvant such as 15 a toxin, a cytokine and a mycobacterial derivative; an oil formulation; a polymer; a micelle forming adjuvant; a saponin; an immunostimulating complex matrix (an ISCOM matrix); a particle; DDA; aluminium adjuvants; DNA adjuvants; y-inulin; and an encapsulating adjuvant. 20

23. The immunogen according to any one of claims 1-20 for use as a pharmaceutical.

24. The immunogenic composition according to claim 22 or 23 for use as a pharmaceutical.

25. Use, in the manufacture of a medicament, of the immunogen 25 according to any one of claims 1-20 or of the immunogenic composition according to claim 21 or 22 for immunizing an animal, including a human being, against an antigen of choice. INTELLECTUAL PROPERTY OFFICE OF N.Z. 13 J AH 2005 REOFiVpn 48

26. The use according to claim 25, wherein the immunogen or the immunogenic composition is adapted to be administered via a route selected from the group consisting of the parenteral route such, as the intracutaneous, the subcutaneous, and the 5 intramuscular routes; the peritoneal route; the oral route; the buccal route; the sublingual route; the epidural route; the spinal route; the anal route; and the intracranial route.

27. The use according to claim 25 or 26, wherein the effective amount of the immunogen in each dosage form is between 0.5 ]ag 10 and 2,000 pg.

28. The use according to any of claims 25-27, wherein the pharmaceutical composition is adapted to be administered at least once per year, such as at least 2, at least 3, at least 4, at least 6, and at least 12 administrations per year. 15

29. The use according to any one of claims 25-28, wherein the immunogen or the immunogenic composition is contained in a virtual lymph node (VLN) device.

30. An immunogen substantially as herein described with reference to the accompanying Examples. 20

31. An immunogenic composition substantially as herein described with reference to the accompanying Examples.